Related Experiment Videos
Chronic myelogenous leukemia: molecule to man.
1Division of Hematology-Oncology, UCLA School of Medicine 90024-1678.
Henry Ford Hospital Medical Journal
|January 1, 1991
Summary
Chronic myelogenous leukemia (CML) is a well-understood cancer driven by ABL proto-oncogene activation. While treatments like chemotherapy and interferon exist, bone marrow transplants offer the best cure rates, especially in the early chronic phase.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) is the most understood human cancer.
- Its molecular basis involves the activation of the ABL proto-oncogene, leading to increased tyrosine kinase activity.
- This results in a clonal expansion of myeloid cells and can progress to acute leukemia.
Purpose of the Study:
- To summarize the molecular underpinnings of CML.
- To discuss current and potential treatment modalities.
- To highlight the prognostic significance of disease phase in treatment efficacy.
Main Methods:
- Review of existing literature on CML.
- Analysis of molecular mechanisms driving leukemogenesis.
- Evaluation of treatment outcomes for chemotherapy, interferon, and bone marrow transplantation.
Main Results:
- ABL proto-oncogene activation is the primary molecular event in CML.
- Chemotherapy and interferon treatments have uncertain impact on survival or cure.
- Bone marrow transplantation cures approximately 50% of CML patients, with higher success rates in the chronic phase.
Conclusions:
- CML pathogenesis is linked to specific genetic alterations.
- Current systemic therapies have limitations in achieving cures.
- Early intervention with bone marrow transplantation offers the best chance for a cure in CML.